GlassScriptPhysician profile
Amanda L Schaffer
NPI 1184066870
$2,248.45
in general payments reported to CMS, 2019-2025
22 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $685 · 2023: $474 · 2024: $727 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.19 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $291.71 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $269.34 | 2023-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $209.67 | 2022-2025 | Farxiga, Lokelma |
| Pfizer INC. | $152.81 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.42 | 2022-2023 | Lifevest |
| Recor Medical INC | $124.06 | 2025 | Paradise Ultrasound Renal Denervation System |
| Astellas Pharma US INC | $111.69 | 2022 | |
| Alnylam Pharmaceuticals INC. | $105.62 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $78.09 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $70.61 | 2022-2023 | Arcalyst |
| Amgen INC. | $69.48 | 2023-2024 | Repatha |
| Abbott Laboratories | $43.97 | 2022-2024 | Cardiomems |
| Merck Sharp & Dohme LLC | $41.67 | 2022-2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $35.01 | 2023-2024 | Inpefa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $28.82 | 2022 | |
| Edwards Lifesciences Corporation | $27.96 | 2023 | |
| Boston Scientific Corporation | $26.43 | 2022 | |
| Medtronic, INC. | $24.18 | 2025 | Micra |
| Chiesi USA, INC. | $21.88 | 2023 | Cleviprex, Kengreal |
| Scpharmaceuticals INC. | $16.00 | 2025 | |
| Novo Nordisk INC | $12.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.